KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Change in Receivables (2017)

Palvella Therapeutics (PVLA) has disclosed Change in Receivables for 3 consecutive years, with $12.1 million as the latest value for Q4 2017.

  • On a quarterly basis, Change in Receivables changed N/A to $12.1 million in Q4 2017 year-over-year; TTM through Sep 2024 was $12.1 million, a N/A change, with the full-year FY2023 number at -$5.3 million, down 302.25% from a year prior.
  • Change in Receivables was $12.1 million for Q4 2017 at Palvella Therapeutics, up from -$44.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $46.5 million in Q2 2017 to a low of -$44.1 million in Q3 2017.
  • A 3-year average of $1.7 million and a median of -$43940.5 in 2014 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 128.06% in 2017; the steepest drop was 128.06% in 2017.
  • Palvella Therapeutics' Change in Receivables stood at -$474418.0 in 2014, then soared by 114.52% to $68870.0 in 2016, then soared by 17515.96% to $12.1 million in 2017.
  • Per Business Quant, the three most recent readings for PVLA's Change in Receivables are $12.1 million (Q4 2017), -$44.1 million (Q3 2017), and $46.5 million (Q2 2017).